Do bisphosphonates reduce the risk of osteoporotic fractures? An evaluation of the evidence to date.
Hodsman
Anthony B
AB
Department of Medicine, University of Western Ontario, London. anthony.hodsman@sjhc.london.on.ca
Hanley
David A
DA
Josse
Robert
R
D000368:Aged; D019386:Alendronate / Q000627:therapeutic use*; D002121:Calcium Channel Blockers / Q000627:therapeutic use*; D012968:Etidronic Acid / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D005260:Female; D050723:Fractures, Bone / Q000209:etiology / Q000517:prevention & control*; D006620:Hip Fractures / Q000209:etiology / Q000517:prevention & control; D006801:Humans; D015663:Osteoporosis, Postmenopausal / Q000150:complications / Q000188:drug therapy*; D000068296:Risedronic Acid; D016103:Spinal Fractures / Q000209:etiology / Q000517:prevention & control; D016896:Treatment Outcome
D002121:Calcium Channel Blockers; D000068296:Risedronic Acid; D012968:Etidronic Acid; D019386:Alendronate